Lajos Pusztai
Yale University
H-index: 121
North America-United States
Top articles of Lajos Pusztai
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Abstract PO2-06-02: Characteristics and Treatment Patterns of de novo Oligometastatic Stage IV Breast Cancer: A Single-Center Retrospective Cohort Study | Cancer Research | Deanna Blansky Maryam Lustberg Lajos Pusztai Mariya Rozenblit | 2024/5/2 |
Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer | Journal of clinical oncology: official journal of the American Society of Clinical Oncology | Alejandro Ríos-Hoyo Erin Cobain Laura A Huppert Peter D Beitsch Thomas A Buchholz | 2024/4/9 |
Abstract PS14-05: Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in … | Cancer Research | Javier Cortés Rebecca Dent Lajos Pusztai Heather McArthur Sherko Kuemmel | 2024/5/2 |
Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial—Efficacy and biomarker discovery | Clinical Cancer Research | Kathy S Albain Christina Yau Emanuel F Petricoin Denise M Wolf Julie E Lang | 2024/2/16 |
Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer | Chowdhury Arif Jahangir David B Page Glenn Broeckx Claudia A Gonzalez Caoimbhe Burke | 2024/1/17 | |
Abstract GS01-01: Biomarker Results in High-risk Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Primary Breast Cancer Following Neoadjuvant … | Cancer Research | Sherene Loi Giuseppe Curigliano Roberto Salgado Roberto Iván Romero Díaz Suzette Delaloge | 2024/5/2 |
Abstract PS06-02: Circulating tumor DNA (ctDNA) monitoring of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high risk breast cancer … | Cancer Research | Lajos Pusztai Ekaterina Kalashnikova Evthokia Hobbs Ursa Brown-Glaberman Monica Mita | 2024/5/2 |
TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan±durvalumab in patients with triple-negative breast cancer and residual invasive disease at … | Therapeutic Advances in Medical Oncology | Aditya Bardia Lajos Pusztai Kathy Albain Eva Maria Ciruelos Seock-Ah Im | 2024/4 |
Abstract A026: An alternative to HER2 IHC 0/1+/2+ status to predict which clinically HER2-negative patients will respond to anti-HER2 therapies: A rationale for the likely … | Cancer Research | Julia Wulfkuhle Denise M Wolf Angela DeMichele Christina Yau Laura van ‘t Veer | 2024/2/1 |
Abstract PO3-02-04: Comparison of OncotypeDX Recurrence Scores (RS) and MammaPrint (MP) scores, and chemotherapy indications in early-stage Estrogen Receptor positive/HER2 … | Cancer Research | Rishika Singh William Barlow Nupur Singh James Elliott Richard Fine | 2024/5/2 |
Abstract PO4-15-08: Comprehensive genomic profiling of HER2-low advanced breast cancers | Cancer Research | Adriana Kahn Ethan Sokol Jeffrey Ross Maureen Pelletier Neal Fischbach | 2024/5/2 |
Immune subtyping identifies a subset of HR+ HER2-early-stage breast cancer patients with a very high likelihood of response to neoadjuvant immunotherapy (IO): Results from 5 IO … | Cancer Research | Denise M Wolf Christina Yau Lajos Pusztai Rita Nanda Jo Chien | 2024/3/22 |
Abstract B077: Subtype-specific signaling dynamics during treatment in non-responding breast cancer patients in the neoadjuvant I-SPY2 TRIAL: are there clues on how to overcome … | Cancer Research | Denise M Wolf Christina Yau Mark Jesus M Magbanua Rosalyn Sayaman Julia Wulfkhule | 2024/2/1 |
Abstract LBO1-01: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated … | Cancer Research | Peter Schmid Javier Cortés Rebecca Dent Lajos Pusztai Heather McArthur | 2024/5/2 |
Abstract PO5-15-04: MammaPrint index predicts neoadjuvant chemosensitivity in patients with HR+ HER2-early-stage breast cancer in the real-world evidence FLEX study | Cancer Research | Joyce O'Shaughnessy Lajos Pusztai Cathy Graham Pat Whitworth Peter Beitsch | 2024/5/2 |
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ | Annals of oncology | Fátima Cardoso S Kyriakides S Ohno F Penault-Llorca P Poortmans | 2019/8/1 |
Immune subtyping in the Response Predictive Subtypes (RPS) identifies a subset of triple negative (TN) early-stage breast cancer patients with a very low likelihood of response … | European Journal of Cancer | DM Wolf C Yau J Haan D Wehkamp A Witteveen | 2024/3/1 |
Abstract PO3-25-08: Artificial Intelligence-based screening of small molecule inhibitors of phosphoenolpyruvate carboxykinase 2 (PCK2), a novel cancer therapeutic target | Cancer Research | Alejandro Rios Hoyo Naing Lin Shan Hao-Kuen Lin Gerson Espinoza Campos Mostafa Ahmed | 2024/5/2 |
Abstract PO5-18-12: Can we cure de novo oligometastatic stage IV HER2+ breast cancer with multimodality therapy?(CHLOE) | Cancer Research | Mariya Rozenblit Nathalie Wiesendanger Kelly Shanahan Christine Hodgdon Peter Gershkovich | 2024/5/2 |
Core Needle Biopsies as an Alternative Source for Ex Vivo Expanded TIL for Adoptive Cell Therapy in Triple-Negative Breast Cancer | Journal of Immunotherapy | Magdalena M Coman Lajos Pusztai Regina Hooley Liva Andreveja Leah Kim | 2024/2/1 |
